pS2 Protein and Tamoxifen Response in Breast Cancer
Author Information
Author(s): I Soubeyran, N Quenel, J-M Coindre, F Bonichon, M Durand, J Wafflart, L Mauriac
Primary Institution: Institut Bergonie, Comprehensive Cancer Center
Hypothesis
Can pS2 protein expression improve the prediction of response to neoadjuvant tamoxifen therapy in post-menopausal breast cancer patients?
Conclusion
pS2 and ER immunohistochemical status are useful tools for predicting tumor regression with neoadjuvant tamoxifen in post-menopausal breast carcinoma patients.
Supporting Evidence
- Univariate and multivariate analysis showed that tumoral regression was linked only to pS2 and ER IHC expression.
- Three groups of tumors were defined based on pS2 and ER positivity, with varying response rates.
- Good response to tamoxifen was defined as tumoral regression greater than 50%.
Takeaway
Doctors can use pS2 protein levels to help decide if tamoxifen will work for older women with breast cancer.
Methodology
Immunohistochemistry was used to study tumor expression of various markers in core biopsies of patients treated with neoadjuvant tamoxifen therapy.
Limitations
Prospective studies are needed to confirm these results.
Participant Demographics
Mean age of participants was 72 years, with a range from 48 to 89 years.
Statistical Information
P-Value
0.004
Statistical Significance
p=0.004
Want to read the original?
Access the complete publication on the publisher's website